WO2002062963A3 - Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same - Google Patents

Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same Download PDF

Info

Publication number
WO2002062963A3
WO2002062963A3 PCT/US2002/003876 US0203876W WO02062963A3 WO 2002062963 A3 WO2002062963 A3 WO 2002062963A3 US 0203876 W US0203876 W US 0203876W WO 02062963 A3 WO02062963 A3 WO 02062963A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
fatty acid
treat
methods
neurologic
Prior art date
Application number
PCT/US2002/003876
Other languages
French (fr)
Other versions
WO2002062963A2 (en
Inventor
Linda D Artman
Original Assignee
Nps Pharma Inc
Linda D Artman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc, Linda D Artman filed Critical Nps Pharma Inc
Priority to AU2002243920A priority Critical patent/AU2002243920A1/en
Priority to EP02709437A priority patent/EP1385520A4/en
Priority to US10/467,700 priority patent/US20040063726A1/en
Priority to CA002437353A priority patent/CA2437353A1/en
Publication of WO2002062963A2 publication Critical patent/WO2002062963A2/en
Publication of WO2002062963A3 publication Critical patent/WO2002062963A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

A method of treating a neurologic or neuropsychiatric disorder or disease in a mammal is provided. The method comprises administering a fatty acid amide hydrolase inhibitor in an amount sufficient to inhibit deamidation of a fatty acid amide. A method of identifying a fatty acid amide hydrolase inhibitor useful in the treatment of a neurologic or neuropsychiatric disorder is also provided. A method of identifying a fatty acid amide or fatty acid useful in the treatment of a neurologic or neuropsychiatric disorder is also provided.
PCT/US2002/003876 2001-02-08 2002-02-08 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same WO2002062963A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002243920A AU2002243920A1 (en) 2001-02-08 2002-02-08 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
EP02709437A EP1385520A4 (en) 2001-02-08 2002-02-08 Methods and compounds for the treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
US10/467,700 US20040063726A1 (en) 2002-02-08 2002-02-08 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
CA002437353A CA2437353A1 (en) 2001-02-08 2002-02-08 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26731001P 2001-02-08 2001-02-08
US60/267,310 2001-02-08

Publications (2)

Publication Number Publication Date
WO2002062963A2 WO2002062963A2 (en) 2002-08-15
WO2002062963A3 true WO2002062963A3 (en) 2002-10-31

Family

ID=23018239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003876 WO2002062963A2 (en) 2001-02-08 2002-02-08 Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same

Country Status (4)

Country Link
EP (1) EP1385520A4 (en)
AU (1) AU2002243920A1 (en)
CA (1) CA2437353A1 (en)
WO (1) WO2002062963A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
PL2076508T3 (en) 2006-10-18 2011-05-31 Pfizer Prod Inc Biaryl ether urea compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798392A (en) * 1996-08-28 1998-08-25 The Board Of Regents Of The University Of Texas System Sulfonyl fluorides for the treatment of Alzheimer's disease
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
US5688825A (en) * 1996-05-31 1997-11-18 University Of Connecticut Anandamide amidase inhibitors as analgesic agents
CN1152677C (en) * 1996-08-30 2004-06-09 Nps药物有限公司 Treatment of spasticity, convulsions by isovaleric acid derivatives CNS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US5798392A (en) * 1996-08-28 1998-08-25 The Board Of Regents Of The University Of Texas System Sulfonyl fluorides for the treatment of Alzheimer's disease
US5798392C1 (en) * 1996-08-28 2002-06-04 Univ Texas Sulfonyl fluorides for the treatment of alzheimer's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBMED [online] US NATIONAL LIBRARY OF MEDICINE, (BETHESDA, MD, USA); LABELLA ET AL.: "Newer concepts of analgesia and anesthesia", XP002954711, accession no. NCBI Database accession no. 6198695 *
PROG. NEUROPSYCHOPHARMACOL. BIOL. PSYCHIATRY, vol. 7, no. 4-6, 1983, pages 647 - 650 *
See also references of EP1385520A4 *

Also Published As

Publication number Publication date
EP1385520A4 (en) 2007-03-21
WO2002062963A2 (en) 2002-08-15
AU2002243920A1 (en) 2002-08-19
CA2437353A1 (en) 2002-08-15
EP1385520A2 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
PL355596A1 (en) Female sexual disorder treating therapies and method of identifying compounds being useful in treating female sexual disorders
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
WO2002002520A3 (en) Compounds to treat alzheimer's disease
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
ATE247117T1 (en) PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL FUNCTION DISORDERS
WO2000002546A3 (en) Use of caba-analogues for treating insomnia
WO2002002506A8 (en) Compounds to treat alzheimer's disease
WO2001066107A3 (en) Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
WO2002032422A3 (en) Ep4 receptor inhibitors to treat rheumatoid arthritis
WO2003032912A3 (en) Treatment of cns disorders using cns target modulators
ATE207352T1 (en) NON-ALLOSTERIC GABA A AGONISTS FOR THE TREATMENT OF SLEEP DISORDERS
WO1999005096A3 (en) Urokinase inhibitors
DE69805973D1 (en) TREATING HEART CRYSTAL DISORDERS BY INHIBITING A MULTIFUNCTIONAL CALCIUM / CALMODULIN-DEPENDENT PROTEIN KINASE
EP1230919A3 (en) Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage
CA2264750A1 (en) Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
BR9714142A (en) Use of matrix metalloproteinase inhibitors to treat neurological disorders and promote wound healing
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
IL143594A0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU2001268233A1 (en) Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
WO2002062963A3 (en) Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2437353

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10467700

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002709437

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002709437

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP